title: Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study.
abstract: BACKGROUND
  Bisphosphonates are common first line medications used for the management of benign bone disease. One of the most devastating complications associated with bisphosphonate use is osteonecrosis of the jaws which may be related to duration of exposure and hence cumulative dose, dental interventions, medical co-morbidities or in some circumstances with no identifiable aggravating factor. While jaw osteonecrosis is a devastating outcome which is currently difficult to manage, various forms of delayed dental healing may be a less dramatic and, therefore, poorly-recognised complications of bisphosphonate use for the treatment of osteoporosis. It is hypothesised that long-term (more than 1 year's duration) bisphosphonate use for the treatment of post-menopausal osteoporosis or other benign bone disease is associated with impaired dental healing.
  
  
  METHODS
  A case-control study has been chosen to test the hypothesis as the outcome event rate is likely to be very low. A total of 54 cases will be recruited into the study following review of all dental files from oral and maxillofacial surgeons and special needs dentists in Victoria where potential cases of delayed dental healing will be identified. Potential cases will be presented to an independent case adjudication panel to determine if they are definitive delayed dental healing cases. Two hundred and fifteen controls (1:4 cases:controls), matched for age and visit window period, will be selected from those who have attended local community based referring dental practices. The primary outcome will be the incidence of delayed dental healing that occurs either spontaneously or following dental treatment such as extractions, implant placement, or denture use.
  
  
  CONCLUSIONS
  This study is the largest case-controlled study assessing the link between bisphosphonate use and delayed dental healing in Australia. It will provide invaluable data on the potential link between bisphosphonate use and osteonecrosis of the jaws.
authors.affiliation: Melbourne Dental School, The University of Melbourne, 720 Swanston Street, Victoria, 3010, Australia. borromeo@unimelb.edu.au
authors.forename: Gelsomina L
authors.initials: GL
authors.lastname: Borromeo
authors.forename: Caroline
authors.initials: C
authors.lastname: Brand
authors.forename: John G
authors.initials: JG
authors.lastname: Clement
authors.forename: Michael
authors.initials: M
authors.lastname: McCullough
authors.forename: Wendy
authors.initials: W
authors.lastname: Thomson
authors.forename: Elly
authors.initials: E
authors.lastname: Flitzanis
authors.forename: John D
authors.initials: JD
authors.lastname: Wark
mesh_terms: D000328:Adult; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D016022:Case-Control Studies; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007568:Jaw / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010020:Osteonecrosis / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D010024:Osteoporosis / Q000188:drug therapy*; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates